DUBLIN–(BUSINESS WIRE)–The “Diabetic Peripheral Neuropathy – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy – Pipeline Review, H1 2020, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.
Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.
The Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 3, 1, 9 and 1 respectively.
Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Report Coverage
- Diabetic Peripheral Neuropathy – Overview
- Diabetic Peripheral Neuropathy – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Diabetic Peripheral Neuropathy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Peripheral Neuropathy – Companies Involved in Therapeutics Development
- Achelios Therapeutics Inc
- Applied Therapeutics Inc
- Bionevia Pharmaceuticals
- Calchan Ltd
- Celularity Inc
- Cleveland Diabetes Care Inc
- Commence Bio Inc
- CSPC Pharmaceutical Group Ltd
- Exodos Life Sciences Limited Partnership
- GNT Pharma Co Ltd
- Grunenthal GmbH
- Immune Pharmaceuticals Inc
- Ion Channel Pharmacology LLC
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Medifron DBT Co Ltd
- Mitsubishi Tanabe Pharma Corp
- Praetego Inc
- Reata Pharmaceuticals Inc
- Seneca Biopharma Inc
- Sonnet BioTherapeutics Inc
- Sphaera Pharma Pte Ltd
- Winsantor Inc
- YD Life Science Co
- Zhejiang Pharmaceutical Co Ltd
- Diabetic Peripheral Neuropathy – Drug Profiles
- (amitriptyline + ketamine hydrochloride) – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Diabetic Peripheral Neuropathy – Dormant Projects
- Diabetic Peripheral Neuropathy – Discontinued Products
- Diabetic Peripheral Neuropathy – Product Development Milestones
- Featured News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ppwkei
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900